Feng Pan1,2, Hong-Jun Luo3, Zhi-Yong Wu4, Su-Zuan Chen5, Xuan Wang1,6, Shuai-Xia Yu1,6, Jia-Min Wang1,6, Shu-Yuan Lin1,6, Ze-Ying Cai1,6, Yu-Lin Gao1,6, Pei-Tong Zhuang1,2, Li-Yan Xu7,8, En-Min Li9,10. 1. Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, 515041, China. 2. Department of Biochemistry and Molecular Biology, Shantou University Medical College, No. 22, Xinling Road, Shantou, 515041, China. 3. Central Laboratory, Shantou University Medical College, Shantou, 515041, China. 4. Department of Tumor Surgery, Shantou Central Hospital, Affiliated Shantou Hospital of Sun Yat-sen University, Shantou, 515031, China. 5. Department of Gastroenterology, The First Affiliated Hospital, Shantou University Medical College, Shantou, 515041, China. 6. Institute of Oncologic Pathology, Shantou University Medical College, No. 22, Xinling Road, Shantou, 515041, China. 7. Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, 515041, China. lyxu@stu.edu.cn. 8. Institute of Oncologic Pathology, Shantou University Medical College, No. 22, Xinling Road, Shantou, 515041, China. lyxu@stu.edu.cn. 9. Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, 515041, China. nmli@stu.edu.cn. 10. Department of Biochemistry and Molecular Biology, Shantou University Medical College, No. 22, Xinling Road, Shantou, 515041, China. nmli@stu.edu.cn.
Abstract
BACKGROUND: Riboflavin deficiency confers a predisposition for esophageal cancer. The role of plasma riboflavin levels in development and prognosis of individuals with digestive tract inflammation and ulcer (DTIU), digestive tract polyps (DTPs), and ESCC is not well understood. METHODS: We performed a cross-sectional study, including 177 DTIU, 80 DTP, and 324 ESCC cases, to measure the plasma riboflavin levels among the three populations. Correlation between plasma riboflavin levels (categorized as ≥31.8, 6.5-31.8 and ≤6.5 nmol/L groups) and clinical characteristics, as well as survival of ESCC patients (556 cases) was analyzed. RESULTS: There was no difference in plasma riboflavin levels between DTIU, DTP, and ESCC cases (P > 0.05). Plasma riboflavin levels were inversely correlated with invasive depth (correlation coefficient = -0.09, P = 0.026) and lymph node metastasis (correlation coefficient = -0.11, P = 0.010) of ESCC, and ESCC patients with low riboflavin levels had poor recurrence-free survival (P = 0.035) and overall survival (P = 0.003). Decreased riboflavin was a prognostic factor for poor overall survival (HR = 1.91, 95% CI = 1.19-3.07, P = 0.007). CONCLUSIONS: Plasma riboflavin levels in DTIU, DTP, and ESCC patients are similar. Plasma riboflavin levels are associated with the development and prognosis of ESCC.
BACKGROUND:Riboflavin deficiency confers a predisposition for esophageal cancer. The role of plasma riboflavin levels in development and prognosis of individuals with digestive tract inflammation and ulcer (DTIU), digestive tract polyps (DTPs), and ESCC is not well understood. METHODS: We performed a cross-sectional study, including 177 DTIU, 80 DTP, and 324 ESCC cases, to measure the plasma riboflavin levels among the three populations. Correlation between plasma riboflavin levels (categorized as ≥31.8, 6.5-31.8 and ≤6.5 nmol/L groups) and clinical characteristics, as well as survival of ESCC patients (556 cases) was analyzed. RESULTS: There was no difference in plasma riboflavin levels between DTIU, DTP, and ESCC cases (P > 0.05). Plasma riboflavin levels were inversely correlated with invasive depth (correlation coefficient = -0.09, P = 0.026) and lymph node metastasis (correlation coefficient = -0.11, P = 0.010) of ESCC, and ESCC patients with low riboflavin levels had poor recurrence-free survival (P = 0.035) and overall survival (P = 0.003). Decreased riboflavin was a prognostic factor for poor overall survival (HR = 1.91, 95% CI = 1.19-3.07, P = 0.007). CONCLUSIONS: Plasma riboflavin levels in DTIU, DTP, and ESCC patients are similar. Plasma riboflavin levels are associated with the development and prognosis of ESCC.
Authors: Kyly C Whitfield; Crystal D Karakochuk; Yazheng Liu; Adrian McCann; Aminuzzaman Talukder; Hou Kroeun; Mary Ward; Helene McNulty; Larry D Lynd; David D Kitts; Eunice C Y Li-Chan; Judy McLean; Timothy J Green Journal: J Nutr Date: 2015-01-07 Impact factor: 4.798
Authors: Hilary J Powers; Marilyn H Hill; Sohail Mushtaq; Jack R Dainty; Gosia Majsak-Newman; Elizabeth A Williams Journal: Am J Clin Nutr Date: 2011-04-27 Impact factor: 7.045